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Brief Clinical ReportsDoes simultaneous lung–liver transplantation provide
an immunologic advantage compared with isolated
lung transplantation?Jay K. Bhama, MD,a Joseph M. Pilewski, MD,b Diana Zaldonis, MPH, BSN,a Paulo A. Fontes, MD,c
Michael E. DeVera, MD,c Michael A. Shullo, PharmD,d Norihisa Shigemura, MD, PhD,a
Christian A. Bermudez, MD,a Yoshiya Toyoda, MD, PhD,a and Kenneth R. McCurry, MD,e Pittsburgh, Pa,
and Cleveland, OhioTABLE 1. Demographics and perioperative data for the control and
study groups
Characteristic
Control
group
(n ¼ 16)
Study
group
(n ¼ 4)
P
value
Preoperative
Age (y) 34.9  9.7 30.7  4.9 .420
Sex
Male 8 (50%) 3 (75%) .591
Female 8 (50%) 1 (25%) .591
Weight (kg) 57.1  11.5 56.7  3.6 .918
Height (in) 65.1  3.7 66.0  2.9 .641
Lung wait time (d) 529  525 363  428 .569
Diagnosis
CF 12 (75%) 3 (75%) .751
PPH 4 (25%) 1 (25%) .751
Operative
Lung ischemic time (min)
First lung 284  68 258  105 .541
Second lung 381  91 334  160 .432
CPB use 8 (50%) 2 (50%) .708
Postoperative
Complications
Tracheostomy 3 (19%) 3 (75%) .061
Bleeding 1 (6%) 0 (0%) .800
Renal insufficiency 4 (25%) 1 (25%) .751
Pneumonia 5 (31%) 2 (50%) .439
LOS
ICU (d) 20  40 37 42 .458
Total (d) 39  36 65  43 .230
No. of TBB in first year 6.5  2.6 5.0  1.6 .283Simultaneous lung–liver transplantation (SLLT) is an un-
common procedure that is limited to patients unable to tol-
erate transplantation of either organ alone. It has been
postulated that same-donor liver transplantation might
provide an immunologic advantage to other simultaneously
transplanted organs. We present our experience with SLLT
comparing immunologic outcomes with those of patients
receiving only lung transplantation to determine whether
such a clinical benefit exists.
CLINICAL SUMMARY
Approval for retrospective review of our transplantation
database was obtained from the University of Pittsburgh
Medical Center Total Quality Control Council. Simulta-
neous lung–liver or heart–lung–liver transplantation was
performed in 4 adults between 2003 and 2006. A control
group was selected based on age, underlying diagnosis,
date of transplantation, and immunosuppressive regimen.
All patients received induction therapy with rabbit antith-
ymocyte globulin, alemtuzumab, or daclizumab. Our proto-
cols for immunosuppression management, diagnosis/
treatment of acute rejection, and infection prophylaxis
have been described previously.1
Fisher’s exact test and an independent t test were used
for qualitative and quantitative variable analysis, respec-
tively. Values are reported as means  standard deviations.
Actuarial survival and freedom from rejection were
calculated by using the Kaplan–Meier method (P< .05,
log-rank test).No. of ACR>2
in first year
11 (69%) 0 (0%) .026
BOS  grade 1 3 (19%) 1 (25%) .837
Mean tacrolimus levels
0–1 mo 12.0  1.4 11.9  1.5 .849
2–3 mo 13.6  1.8 10.8  1.6 .012
4–6 mo 12.8  2.4 11.7  2.3 .435
7–12 mo 12.1  2.9 11.5  3.4 .774
13–24 mo 12.5  1.9 10.8  1.6 .115
25–36 mo 10.7  2.4 12.1  2.9 .337
CF, Cystic fibrosis; PPH, primary pulmonary hypertension; CPB, cardiopulmonary
bypass; LOS, length of stay, ICU, intensive care unit; TBB, transbronchial biopsy;
ACR, acute cellular rejection; BOS, bronchiolitis obliterans syndrome.
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FIGURE 1. Kaplan–Meier survival plots comparing rejection-free survival (A) and patient survival (B) for the control and study groups.
Brief Clinical ReportsDemographic and perioperative characteristics for the
study and control groups are described in Table 1. The
incidence of acute cellular rejection (grade>2) in the first
year after transplantation was significantly higher in the
control group compared with that seen in the study group
(68.8% vs 0%, P ¼ .026). One patient in the study group
had bronchiolitis obliterans syndrome at 18 months neces-
sitating repeat double-lung transplantation after 2.3 years.
Both groups had similar mean tacrolimus levels postoper-
atively, although the study group had significantly lower
tacrolimus levels during months 1 to 3. Rejection-free
survival was better in the study group compared with the
control group during the first year, but by the third year,
there was no difference between the 2 groups (Figure 1,
A). There were no operative mortalities in either group,
and Kaplan–Meier survival estimates were similar
(Figure 1, B).
DISCUSSION
Despite the encouraging results observed in recent
years with lung transplantation, coexisting severe hepatic
dysfunction remains a contraindication. The challenge
associated with management of multiorgan disease cou-
pled with the shortage of organs has led to a disinterest
in SLLT. However, for some patients, this remains the
only option for extending life and improving quality
of life.
Previous experience with this tour de force of transplan-
tation has been limited to small case series.2-4 The report by
Faro and colleagues3 in 5 children with SLLT demonstrated
lower rates of acute rejection and bronchiolitis obliterans
syndrome compared with those seen in children receiving
isolated lung transplantation. However, no study in adults
has provided a similar comparison.
In our experience a potent early immunologic advan-
tage was noted in patients who received SLLT comparedThe Journal of Thoracic and Cawith those undergoing isolated lung transplantation.
This effect was noted despite both groups having similar
tacrolimus levels. Interestingly, during months 2 to 3
after transplantation, lung–liver transplants were able
to be maintained rejection free with significantly lower
levels of tacrolimus compared with patients receiving
isolated lung transplantation. Unfortunately, this effect
was transient, and by the third year, there was no differ-
ence in the incidence of acute rejection between the
groups.
Previous studies by Calne5 described the phenomenon
of donor-specific immunologic protection provided by
the liver. This has been attributed to numerous mecha-
nisms, including the release of soluble histocompatibility
antigens by the liver that are capable of inducing a state
of tolerance and induction of microchimerism by passen-
ger leukocytes within the liver. A similar immunologic
privilege has been noted in multiorgan transplantation,
including combined heart–kidney and heart–lung trans-
plantation in which acute rejection of the heart has
been lower than with isolated heart transplantation.
This explanation exploits the potential for a large burden
of foreign tissue to create a state of anergy within the
recipient.
The clinical success noted in this and other studies aug-
mented by a potential immunologic advantage creates an at-
tractive option for patients with end-stage liver and lung
disease. Unfortunately, our limited understanding of immu-
nologic tolerance and the transient nature of this effect
remain formidable obstacles. An additional obstacle is sur-
viving to transplantation. Although no patients died while
awaiting transplantation, other studies have reported wait-
list mortalities.3
In conclusion, SLLT can be performed safely, with good
early to midterm outcome. Same-donor liver transplantation
might offer an immunologic advantage to simultaneouslyrdiovascular Surgery c Volume 141, Number 5 e37
Brief Clinical Reportsperformed lung transplantation. Further clinical and experi-
mental studies are warranted to better understand the poten-
tial benefits, as well as the mechanisms by which they are
mediated.
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